Search the Newsreel

Bilibili Number of Employees 2026 | Employee Count & Headcount Data

Bilibili, Inc. (9626) has approximately 8,352 total employees worldwide as of March 2026, marking an 11.9% decline since 2023. Despite this, the company is actively hiring, with 282 active job postings in 2026, a 24.3% increase from the previous year. The workforce is primarily …

Ibiden Co.,Ltd. Stock (IBI0) - Quote Deutsche Boerse AG

Bilibili Inc. Sponsored ADR $BILI Stake Decreased by Optiver Holding B.V.

Optiver Holding B.V. significantly reduced its stake in Bilibili Inc. (BILI) by 67.5% in the first quarter, selling 187,612 shares. Despite this reduction, institutional investors and hedge funds collectively own 16.08% of Bilibili. The stock maintains a "Moderate Buy" consensus rating from analysts, with …

Bilibili Inc. Sponsored ADR $BILI Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC significantly increased its stake in Bilibili Inc. (NASDAQ:BILI) by 121.1% in the first quarter of 2026, acquiring an additional 277,900 shares and bringing its total holdings to 507,335 shares valued at $11.45 million. Other institutional investors also moderately increased their positions, …

Perceptive Advisors LLC Sells 3,106,568 Shares of Inhibikase Therapeutics, Inc. $IKT

Perceptive Advisors LLC significantly reduced its stake in Inhibikase Therapeutics (NASDAQ:IKT) by selling over 3.1 million shares, though other institutional investors like Sands Capital Alternatives and ADAR1 Capital Management increased their holdings. Despite this sale, analyst sentiment remains largely positive with an average "Buy" …

Inhibikase Therapeutics, Inc. Revenue Breakdown – NASDAQ:IKT

This article provides a basic financial overview for Inhibikase Therapeutics, Inc. (NASDAQ:IKT) on TradingView. It indicates that the market is closed, with no current trades. The content primarily lists available financial data categories and links to various TradingView products and community features, rather than …

BILI|Bilibili Inc|Price:19.070|

Bilibili Inc. (BILI) has a relatively healthy fundamental outlook and high growth potential, though its stock is considered fairly valued within the Software & IT Services industry. Analysts have rated it a "Buy" with a target price suggesting a 54.82% upside, despite expectations of …

18,030,000-share swap for warrant by Inhibikase Therapeutics, Inc. (IKT)

RA Capital Healthcare Fund, L.P., a ten percent owner of Inhibikase Therapeutics, Inc. (IKT), executed an Exchange Agreement on July 29, 2026. The fund swapped 18,030,000 shares of common stock for a pre-funded warrant exercisable for the same number of shares at $0.001 per …

RA Capital group (NASDAQ: IKT) discloses 9.99% capped stake via stock and warrants

RA Capital Management, L.P., along with RA Capital Healthcare Fund, L.P., Peter Kolchinsky, and Rajeev Shah, have disclosed a beneficial ownership of 14,653,994 shares, capped at 9.99%, in Inhibikase Therapeutics, Inc. (IKT) through stock and pre-funded warrants. The pre-funded warrants include a "Beneficial Ownership …

H.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug status

H.C. Wainwright has reiterated a Buy rating and an $8.00 price target for Inhibikase Therapeutics Inc (NASDAQ:IKT) after the company received FDA Orphan Drug Designation for IKT-001, its lead product candidate for pulmonary arterial hypertension. This designation provides significant incentives and potential market exclusivity. …

Bilibili Inc (BILI) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Bilibili Inc (BILI), focusing on its support and resistance levels, various technical indicators, and moving averages. The stock's current price momentum score is 3.34, and it is trading between resistance at 19.55 and support at 17.39. Technical …

Bilibili Inc (BILI) Institutional Confidence

Bilibili Inc's institutional confidence score is 3.00, placing it 283rd out of 485 in the Software & IT Services industry. The institutional shareholding proportion has decreased by 57.58% quarter-over-quarter to 9.09%. James Simons is currently the largest institutional shareholder, despite a 20.27% decrease in …

Inhibikase Therapeutics Inc (IKT) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Inhibikase Therapeutics Inc's (IKT) financial health, ranking it 237 out of 384 in the Biotechnology & Medical Research industry. The company's financial status is described as robust, but its operating efficiency is low. Key financial metrics such as …

iBio Inc (IBIO) Institutional Confidence

iBio Inc's institutional confidence score is 5.00, placing it 132nd in the Biotechnology & Medical Research industry. Institutional shareholding decreased by 7.72% quarter-over-quarter, with the largest individual shareholder being Bill Nygren | OAKMX, although their holdings significantly decreased. Several other institutions hold substantial shares, …

ADAR1 Capital Management LLC Reduces Stock Position in Inhibikase Therapeutics, Inc. $IKT

ADAR1 Capital Management LLC significantly reduced its stake in Inhibikase Therapeutics (NASDAQ:IKT) by 18.1% in the first quarter, selling over 1.4 million shares. Despite this reduction, other institutional investors like BNP Paribas Financial Markets, Barclays PLC, and Virtu Financial LLC increased their positions. The …

IKT|Inhibikase Therapeutics Inc|Price:2.217|Chg%:-0.093

Inhibikase Therapeutics Inc (IKT) shows strong fundamentals and high growth potential, despite recent technical trends not fully supporting its performance. The company is considered fairly valued and has high institutional ownership. Analysts have given it a "Buy" rating with a target price indicating significant …

Inhibikase Therapeutics Inc (IKT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Inhibikase Therapeutics Inc (IKT), highlighting its current valuation score of 6.53 and its ranking within the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -5.42, which is significantly below its recent high and …

Unibios Holdings S.A. Revenue Breakdown – ATHEX:BIOSK

IBIO|iBio Inc|Price:1.385|Chg%:-0.065

iBio Inc (IBIO) is a preclinical stage biotechnology company using AI for precision antibody development, with a focus on immuno-oncology. Despite recent market underperformance, the company shows strong fundamentals, high growth potential, and a "Buy" rating from analysts with significant upside. IBIO's stock is …

iBio Inc (IBIO) Balance Sheet

This article provides a detailed balance sheet for iBio Inc (IBIO), presenting quarterly and annual financial data. It allows users to analyze the company's financial health, including assets, liabilities, and shareholders' equity over several financial years. The page also includes FAQs explaining key balance …

iBio Inc (IBIO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed look into the shareholder structure of iBio Inc (IBIO), highlighting its major shareholders and institutional holdings. It lists the top five shareholders by proportion, including Affinity Asset Advisors LLC and EcoR1 Capital, LLC, and categorizes shareholders by type such …

IKT|Inhibikase Therapeutics Inc|Price:2.330|

This article provides an analysis of Inhibikase Therapeutics Inc (IKT), highlighting its healthy fundamentals, high growth potential, and "Buy" rating from analysts with a target price of $6.00. Despite strong stock performance and outperforming fundamentals, technical indicators suggest the stock is trading sideways, suitable …

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

Inhibikase Therapeutics (Nasdaq: IKT) announced that the FDA has granted Orphan Drug Designation (ODD) to its lead product candidate IKT-001 for the treatment of Pulmonary Arterial Hypertension (PAH). This designation highlights the significant unmet medical need for the approximately 50,000 PAH patients in the …

Bilibili Inc (BILI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Bilibili Inc (BILI), detailing its performance by business segments and geographic region. As of FY2024, the company generated 40.99% of its revenue from Live broadcasting and VAS, 30.52% from Advertising, 20.91% from Mobile Game, and 7.58% from …

Inhibikase Therapeutics Inc (IKT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of the dividend and stock split history for Inhibikase Therapeutics Inc (IKT). It notes that the company has not distributed any dividends in the past five years. The article also details multiple 6-to-1 merger-based stock splits that occurred on …

Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Sell at Wall Street Zen

Wall Street Zen has upgraded Inhibikase Therapeutics (NASDAQ:IKT) from "strong sell" to "sell." This decision comes amidst varied analyst opinions, with some maintaining "sell" ratings while others have initiated "strong-buy" or "outperform" ratings with price targets of up to $5.00. The company's stock opened …

iBio, Inc. Revenue Breakdown – TRADEGATE:0JV0

iBio, Inc.'s revenue breakdown shows that in the last year, the company generated 339.56K EUR, primarily from its Precision Antibodies segment which also saw 210.06K EUR the previous year. All of this revenue was attributed to the United States market.

TradingKey

This page from TradingKey provides a detailed income statement for iBio Inc (IBIO), showing quarterly and annual financial data from FY2012Q1 through FY2026Q3. It includes metrics such as total revenue, operating expenses, research and development expenses, net income, and earnings per share. The page …

BILI|Bilibili Inc|Price:17.160|Chg%:-0.330

Bilibili Inc. (BILI) closed at $17.160, down 1.89%, with a market cap of $7.18 billion. The company shows strong fundamentals with steady revenue growth and a turnaround to profitability, though institutional selling has occurred recently. Analysts maintain a "Buy" rating with a target price …

iBio Inc (IBIO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of iBio Inc (IBIO), showing its current valuation score, market capitalization, and stock price. It highlights the company's P/E ratio and notes that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed. The valuation …

Bilibili, Inc. Class Z (9626) Receives a Buy from Morgan Stanley

Morgan Stanley has reiterated a Buy rating on Bilibili, Inc. Class Z (9626) with a price target of HK$241.80. The company currently holds a Strong Buy consensus among analysts, with a price target of HK$227.74. Bilibili recently reported a quarterly revenue of HK$7.4 billion …

Chardan Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5

Chardan Capital has reiterated its Buy rating for IBio Inc (IBIO.US), maintaining a target price of $5. This indicates the firm's continued confidence in the company's stock performance.

Inhibikase's IKT-001 gets FDA orphan designation for PAH, about 50,000 Americans

Inhibikase Therapeutics announced that its lead product candidate, IKT-001, has received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of Pulmonary Arterial Hypertension (PAH), a condition affecting approximately 50,000 Americans. This designation provides incentives such as tax credits, exemption from FDA …

'Jujutsu Kaisen Phantom Parade' Launches 1.5th Anniversary Part 3 Update

Bilibili has launched the 1.5th anniversary Part 3 update for the global version of 'Jujutsu Kaisen Phantom Parade', a turn-based card RPG. This update includes up to 140 free draws, two new SSR characters (Itadori Yuji and Gojo Satoru), an original event story set …

Bilibili Q2 2026 Preview: High-Engagement Community Driving Ad Monetization; Reiterate Buy

Bilibili is expected to report strong Q2 2026 earnings, driven by its engaged user base, membership growth, and new ad monetization features like Pause Ads. Despite trading at a premium 20.6x 2027E forward multiple, the company's high engagement and expanding commercial value justify this …

Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

This article is a preliminary proxy statement (PRE 14A) filed by Inhibikase Therapeutics. The document pertains to a merger or acquisition, indicating that the company is involved in a corporate transaction that requires shareholder approval or notification. The specific details of the merger or …